cas 454248-53-4|| where to buy (R)-3-boc-4-methyl-2,2-dioxo-[1,2,3]oxathiazolidine

Nom du produit:(R)-3-boc-4-methyl-2,2-dioxo-[1,2,3]oxathiazolidine

IUPAC Name:tert-butyl (4R)-4-methyl-2,2-dioxo-1,2λ⁶,3-oxathiazolidine-3-carboxylate

Unité d'emballage	Stock disponible	Prix($)
CM108014-10g	in stock	ȋǠ
CM108014-25g	in stock	ƻȋŭ
CM108014-100g	in stock	Ʃƅș

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 454248-53-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:454248-53-4; Formule moléculaire:C8H15NO5S; Point de fusion:-; Code SMILES:O=S1(OC[C@@H](C)N1C(OC(C)(C)C)=O)=O; Densité:

: Numéro de catalogue:CM108014; Poids moléculaire:237.27; Point d'ébullition:; N° Mdl:MFCD09864994; Stockage:

: Thiazolidines; Thiazolidine is a heterocyclic organic compound, which is a five-membered saturated ring with a thioether group and an amine group. It is the sulfur analog of oxazolidine. Thiazolidine derivatives have many uses and have a broad spectrum of biological activities. For example, the drug pioglitazone contains a thiazolidine ring. Thiazolidine has three isomers, 2-, 3-, and 4-. Derivatives with a 2-thiazoline ring are the most common.

: Alicyclic Heterocycles; When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.

: Giredestrant; Giredestrant (GDC-9545) is under development by Roche/Genentech. Giredestrant is a potent, next generation investigational selective oestrogen receptor (SERD) with best-in-class potential. In the phase 2 coopERA trial, postmenopausal patients with untreated ER+/HER2- early breast cancer were randomly assigned to receive neoadjuvant combination therapy with palbociclib and giredestrant or anastrozole, followed by surgical intervention within 14 days. The tumor biomarker Ki67 of the patients was ≥ 5% when they were enrolled in the group. The analysis showed that patients receiving giredestrant combination therapy (mean Ki67 reduction of 80%) had a greater mean reduction in Ki67 levels from baseline at week 2 compared with anastrozole combination therapy (mean Ki67 reduction of 67%). The pivotal phase 3 trial of giredestrant is recruiting patients and preliminary data is expected in 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

: Camizestrant; Recently, Evaluate Pharma released an analysis report on the trends in the biopharmaceutical industry in 2024. The report mentioned 10 potential key R&D pipelines, including the small molecule drug camizestrant. Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.